Dr. George H. Poste, D.V.M., Ph.D., F.R.C. Path, F.R.S., has been the Chief Executive Officer at Health Technology Networks since 1999. Dr. Poste serves as a Senior Technical Advisor of Caris, Ltd. Dr. Poste is Special Limited Partner at Care Capital, LLC. He also serves as the Chief Scientific Advisor at Caris Life Sciences Inc. He serves as Del E. Webb Chair of Health Innovation at Arizona State University. In February 2009, he assumed the post of Chief Scientist of Complex Adaptive Systems Initiative (CASI) at Arizona State University. He founded the Boidesign Institute at ASU and served with it from 2003 to 2008. In creating this Institute, he designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $225 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering. From 1992 to 1999, he served as the Chief Science and Technology Officer and President of R&D at SmithKline Beecham Limited (SB). He held other positions at SmithKline Beecham or its related entities. During his tenure at SmithKline Beecham, he was associated with the successful registration of 31 drug, vaccine and diagnostic products. He has been the Non-Executive Chairman of Structural GenomiX, Inc. since 2000. He serves as the Chairman of Scientific Advisory Board at Archemix Corp., and Caris Life Sciences, Inc. He served as Non-Executive Chairman of Caris Molecular Diagnostics since August 2008. He served as Chairman of the Board at SGX Pharmaceuticals, Inc., and Cerebrus Pharmaceuticals Limited. He served as the Chairman of Diadexus, Inc. since September 1997. He served as the Chairman on the Board of Maxygen, Inc. and Illumina Inc. Dr. Poste served as the Chairman of Orchid BioSciences, Inc. (now Cellmark Forensics, Inc.) from 2002 to August 25, 2009. He serves as Vice Chairman at Caris Life Sciences, Inc. He served as Vice Chairman of Miraca Life Sciences, Inc. Dr. Poste has been an Independent Director at Monsanto Company since February 2003. He has been an Independent Director of Exelixis, Inc. since August 2004. He serves as a Director at Caris Life Sciences, Inc. Dr. Poste serves as Member of Scientific Advisory Board at Haplogen GmbH. He serves as a Member of Scientific Advisory Board at Synthetic Genomics, Inc., Anacor Pharmaceuticals, Inc., and Boston BioCom LLC. He serves as Member of the Editorial Advisory Board at RJ Communications and Media Ltd. He serves as a Member of the Clinical and Scientific Advisory Board of Human Longevity, Inc. He serves as a Member of Advisory Board at Burrill Biotechnology Capital Fund I, L.P., Burrill Life Sciences Capital Fund III, L.P., Burrill Life Sciences Capital Fund II, L.P. and Burrill Biotechnology Capital Fund II, L.P. He served as a Director of Maxygen, Inc. He served as a Director at Orchid Biosciences Inc. since March 2000 until August 25, 2009. He served as an Outside Director of Miraca Life Sciences, Inc. since November 2006. He served as a Director and Member of Scientific Advisory Board at Molecular Profiling Institute, Inc. He served as a Director of CaremarkPCS, LLC since July 2002. He served as a Director of Anacor Pharmaceuticals, Diadexus and CMDx. He served as a Director at Orchid Cellmark Inc. from March 2000 to August 25, 2009 and Caremark Rx, L.L.C. since March 24, 2004. He served as a Director of SmithKline Beecham Ltd. He is a Co-Founder of Cancer and editorial board Metastasis Reviews and Advanced Drug Delivery Reviews. He chairs the Department of Defense Task Force on the Protection of the United States against Bioterrorism. He was the Chairman of the journal, Nature BioTechnology. He serves on the editorial boards of several journals and also writes a regular column for the Financial Times. He is a member of the Council on Foreign Relations. He is a Member of the National Academy Sciences Working Group on Biological Weapons, the Forum on Microbial Threats of the Institute of Medicine Board on Global Health and the Institute of Medicine Committee on Advances in Technology and Next Generation Biowarfare Threats. He also has served a number of National Academy panels related to national security. Dr. Poste was a Member of the Defense Science Board and the Health Board of the U.S. Department of Defense. He was a Director of Arizona Biodesign Institute from May 2003 to February 2009. He is a Research Professor at the University of Pennsylvania, the William Pitt Fellow at Pembroke College, Cambridge University. He is also a Regents' Professor and Del E. Webb Distinguished Professor of Biology at Arizona State University, Skysong. He is a Professor of Complex Adaptive Systems Initiative at Arizona State University-Tempe. Dr. Poste has published over 350 scientific papers and co-edited 14 books on pharmaceuticals, technology and oncology. He is a Board Certified Pathologist. He is a Fellow of University College, London. He is a Fellow of the Royal Society and The Royal College of Pathologists and a distinguished Fellow at the Hoover Institution, Stanford University. He is also a Fellow of the Academy of Medical Sciences in the U.K. He has received honorary degrees in Science and Law for his research contributions and was awarded the rank of Commander of the British Empire by HM Queen Elizabeth II for his services to international health. In 2004, he was named as ‘R&D Scientist of the Year’ by R&D Magazine and in 2006. He is Recipient of the Scrip Lifetime Achievement Award (2009) and named Scientist of the Year by R&D Magazine (2004). He received the Einstein award from the Global Business Leadership Council. Dr. Poste received a Doctorate in Veterinary' Medicine in 1966 and a Ph.D. in Virology in 1969 from the University of Bristol.

 Pharmaceutical Sciences